Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 9Paclitaxel 9Doxorubicin 6Cyclophosphamide 6Carboplatin 5130-nm albumin-bound paclitaxel 5durvalumab 3yeast-CEA vaccine 2talazoparib 2sacituzumab govitecan 2olaparib 2glembatumumab vedotin 2avelumab 2Taxes 2Radiotherapy 2Leucovorin 2Fluorouracil 2Cisplatin 2Capecitabine 2Biopsy 2Albumin-Bound Paclitaxel 2ALT-803 2zimberelimab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab duocarmazine 1tislelizumab 1taxane 1sabizabulin 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Triple Negative Breast Neoplasms × CR011-vcMMAE × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡